Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study
Yanyan Li, Shuai‐Shuai Ge, Yuan-Hong Huang, Mingzhu Xu, Chao‐Ling Wan, Kai-Wen Tan, Tao Tao, Haixia Zhou, Shengli Xue, Haiping Dai
Abstract
The 3-year overall survival for patients with primary refractory or relapsed acute myeloid leukemia (R/R AML) is only approximately 10% [ 1 ]. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment for R/R AML, but has a high post-transplant relapse in patients who received transplant with active disease. Reduction of pre-transplant leukemia burden by salvage therapy can reduce post-transplant relapse [ 2 ]. Conventional salvage chemotherapy often has a low response rate but high organ toxicities [ 3 ]. Therefore, exploring novel salvage regimens to bridge allo-HSCT may help improve the prognosis of R/R AML.